RecruitingPHASE1, PHASE2NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Studying Adamantinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Parabilis Medicines, Inc.
- Principal Investigator
- Jorge Ramos, DO, MDParabilis Medicines, Inc.
- Intervention
- FOG-001(drug)
- Enrollment
- 595 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (23)
- Honor Health, Scottsdale, Arizona, United States
- Arizona Cancer Center at University of Arizona, Tucson, Arizona, United States
- Stanford Cancer Institute, Stanford University, Palo Alto, California, United States
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- Sarcoma Oncology Center, Santa Monica, California, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Johns Hopkins University, Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
- Florida Cancer Specialists, Lake Mary, Florida, United States
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, Ohio, United States
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05919264 on ClinicalTrials.govOther trials for Adamantinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05286788MEKTOVI® for the Treatment of Pediatric Adamantinomatous CraniopharyngiomaNationwide Children's Hospital
- RECRUITINGPHASE2NCT05233397ACTEMRA® for the Treatment of Pediatric Adamantinomatous CraniopharyngiomaNationwide Children's Hospital
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT03970226Tocilizumab in Children With ACPUniversity of Colorado, Denver